Item 7.01 Regulation FD Disclosure.

On January 4, 2021, Pandion Therapeutics, Inc. (the "Company") issued a press release announcing topline data from its Phase 1a clinical trial of PT01 in healthy volunteers. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The Company will host a conference call to discuss the topline data on January 4, 2021 at 8:30 a.m. ET, and a webcast of the call will be available through the investor relations section of the Company's website.

On January 4, 2021, the Company posted a presentation on the "Investors & Media" section of the Company's website (www.pandiontx.com). The information contained in, or that can be accessed through, the Company's website is not a part of this filing. A copy of the presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 7.01, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibit is furnished herewith:





        99.1     Press Release issued by the Company on January 4, 2021

        99.2     Presentation dated January 4, 2021

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses